HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Entrada Therapeutics (NASDAQ:TRDA) and maintained a $25 price target.
September 22, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Entrada Therapeutics (NASDAQ:TRDA) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $25.
The reiteration of a 'Buy' rating and maintenance of a $25 price target by HC Wainwright & Co. indicates a positive outlook for Entrada Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100